Retatrutide in 2026: The Triple Agonist That's Rewriting Weight Loss Science
Retatrutide produced 24.2% body weight loss in Phase 2 — the largest ever recorded in an obesity drug trial. Here's what the research shows about how it works, how it compares to tirzepatide and semaglutide, and what's coming in Phase 3.